Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Petros Christopoulos"'
Autor:
Farastuk Bozorgmehr, Antje Blank, Walter E. Haefeli, Michael Thomas, Petros Christopoulos, Jürgen Burhenne, Nicolas Hohmann, Gerd Mikus
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 487-491 (2021)
Clinical and Translational Science
Clinical and Translational Science
The inhibitor of anaplastic lymphoma kinase (ALK) crizotinib significantly increases survival in patients with ALK-positive non-small cell lung cancer (NSCLC). When evaluating crizotinib pharmacokinetics (PKs) in patients taking the standard flat ora
Autor:
David Fisch, Farastuk Bozorgmehr, Daniel Kazdal, Jonas Kuon, Laura V. Klotz, Rajiv Shah, Florian Eichhorn, Mark Kriegsmann, Marc A. Schneider, Thomas Muley, Albrecht Stenzinger, Helge Bischoff, Petros Christopoulos
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundLarge-cell neuroendocrine lung carcinoma (LCNEC) is a rare pulmonary neoplasm with poor prognosis and limited therapeutic options.MethodsWe retrospectively analyzed all patients with metastatic LCNEC in the records of a large German academi
Autor:
Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, Jonas Kuon, Daniel Kazdal, Hannah Schindler, Rajiv Shah, Anna-Lena Volckmar, Fabienne Lusky, Leonore Diekmann, Stephan Liersch, Martin Faehling, Thomas Muley, Mark Kriegsmann, Karolina Benesova, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
IntroductionPD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAEs) that complicate management.MethodsWe analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012
Autor:
M. Elshiaty, Michael Meister, C. Andreadis, Lena Gaissmaier, Ilias Athanasiadis, Farastuk Bozorgmehr, K. Samitas, A. Stenzinger, Helena Linardou, Giannis Mountzios, Georgios Pentheroudakis, Epaminontas Samantas, Sofia Baka, Harland S. Winter, Martin Reck, Helge Bischoff, Sophia Agelaki, K. Senghas, Georgios Oikonomopoulos, E. Zervas, J. Kuon, Mark Kriegsmann, L. Daniello, Paris Kosmidis, Anastasia Christopoulou, Amanda Psyrri, C.P. Heussel, Kostas N. Syrigos, E.-I. Perdikouri, Fjf Herth, E. Razis, Michael Thomas, R. El Shafie, Thomas Muley, Petros Christopoulos, Christos Emmanouilidis, Z. Saridaki, E. Lianos, I. Boukovinas, Johannes Krisam, Elena Fountzilas, Katharina Kriegsmann
Publikováno v:
Journal of Thoracic Oncology. 16:S573-S574
Autor:
Deniz Tural, Terry L. Ng, Noemi Reguart, Ömer Fatih Ölmez, Ozgur Ozyilkan, Ahmet Sezer, Ilhan Oztop, Mehmet Ali Kaplan, Laila C. Roisman, E. Filippova, Irfan Cicin, Aziz Karaoglu, Umut Demirci, Petros Christopoulos, Elizabeth Dudnik, Fatma Buğdaycı Başal, Perran Fulden Yumuk, D.R. Camidge, Sergei V. Orlov, Mehmet Ali Nahit Sendur, Nezih Meydan, Saadettin Kilickap, Mustafa Erman, Oliver Gautschi, Havva Yesil Cinkir, Patrizia Froesch, Kerem Okutur, Ismail Beypinar, Nir Peled, Kübra Aydın, Devrim Cabuk, Julien Mazieres, Hasan Şenol Coşkun, Alisan Zirtiloglu, Hande Turna, Taner Korkmaz, Abdurrahman Isikdogan, Roni Gillis, Ahmet Demirkazik, R. Grinberg, Doğan Yazılıtaş, Cengiz Yilmaz, Adnan Aydiner, Yesim Eralp, Semra Paydas, Filiz Çay Şenler, Ibrahim Yildiz, Moiseenko Fedor
Publikováno v:
Web of Science
Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. the FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa5766b0b6f75e47142bb5ab9ba635fc
https://hdl.handle.net/11454/61883
https://hdl.handle.net/11454/61883
Autor:
Petros Christopoulos, Yasushi Goto, Luis Paz-Ares, Jason Baum, Edward B. Garon, A. Ardizzoni, P. Cazorla Arratia, Shun Lu, Michael Thomas, J.C.-H. Yang, Yvonne Y. Lau, C. Zheng, P. De Marchi, Spigel, Fabrice Barlesi, Byoung Chul Cho, A Kay
Publikováno v:
60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Autor:
Rami A El Shafie, Felix J.F. Herth, Farastuk Bozorgmehr, Petros Christopoulos, Sophie Aufderstrasse, Juliane Hörner-Rieber, Jürgen Debus, Stefan Rieken, Denise Bernhardt, Sebastian Adeberg, Jutta Kappes, Michael Thomas, Laila König, Martin Steins
Publikováno v:
Cancer Management and Research
Denise Bernhardt,1–3,* Sophie Aufderstrasse,1,2,* Laila König,1–3 Sebastian Adeberg,1–4 Farastuk Bozorgmehr,5,6 Petros Christopoulos,5,6 Rami A El Shafie,1,2 Juliane Hörner-Rieber,1–3 Jutta Kappes,6,7 Michael Thomas,5,6 Felix Herth,6,7 Mart
Autor:
S. Liersch, Mark Kriegsmann, Philipp Mayer, Hans-Ulrich Kauczor, Helge Bischoff, Claus Peter Heussel, Stephan Rheinheimer, Thomas Muley, Hauke Winter, Petros Christopoulos, Rami A El Shafie, Farastuk Bozorgmehr, Felix J.F. Herth, Albrecht Stenzinger, Michael Thomas, Lena Gaissmaier
Publikováno v:
Cancers, Vol 12, Iss 1046, p 1046 (2020)
Cancers
Volume 12
Issue 4
Cancers
Volume 12
Issue 4
Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival. In order to characterize OPD in immunotherapy (I
Autor:
Hartmut Bertz, Miguel Waterhouse, Reinhard Marks, Claudia Schmoor, Jürgen Finke, Ralph Wäsch, Petros Christopoulos
Publikováno v:
Bone Marrow Transplantation. 48:901-907
A second allograft was offered to 58 relapsed AML patients after conditioning with fludarabine 90-150 mg/m(2) and thiotepa 15 mg/kg, in most cases with active disease. Median age was 53 years (range 23-69), median time to relapse after the first allo
Autor:
Jürgen Finke, Reinhard Marks, Petros Christopoulos, Gabriele Ihorst, Ralph Wäsch, Hartmut Bertz
Publikováno v:
Biology of Blood and Marrow Transplantation. 18(9):1430-1437
Total body irradiation has been the mainstay of conditioning since the inception of allogeneic hematopoietic cell transplantation, but toxicity often precludes its use. For less-fit patients with acute lymphoblastic leukemia and other hematologic mal